Evolving Considerations in lmmuno-Oncology:

Bridging the Gaps Between Research and Clinical Care

A Global Educational Initiative for Healthcare Providers

Banner Image
Video thumbnail

Transcripts available in 6 languages (Select one below):

This activity is supported by educational grants from Pfizer Inc and EMD Serono.

A Video Spotlight Expert Panel Discussion

Featuring Adi Diab, MD (Course Director); Mark M. Awad, MD, PhD; Arjun V. Balar, MD; and Nizar M. Tannir, MD, FACP

Transcripts Available in 6 Languages!

OVERVIEW

Over the past decade, there has been a tremendous paradigm shift in cancer treatment driven by advances in immuno-oncology (IO). At the forefront of these developments are the monoclonal antibody-based immune checkpoint inhibitors (ICIs). Collectively, these agents have led to well-tolerated and durable clinical benefits in patients with historically hard-to-treat advanced cancers, including lung cancer, urothelial carcinoma, renal cell carcinoma, and melanoma. Immuno-oncology is poised to advance even further, with the ongoing evaluation of ICIs and novel ICI combination modalities in a number of other advanced malignancies for which treatment options remain limited. Join 4 immunotherapy experts for an intimate discussion of the latest scientific evidence and perspectives related to advances in immunotherapy across a variety of solid tumors, including bladder cancer, lung cancer, ovarian cancer, renal cell carcinoma, and skin cancer, and the potential subsequent implications for practice and patient care. This expert panel discussion will also address unique response patterns associated with ICIs, the role of biomarker testing in predicting treatment response, and strategies to effectively identify, manage, and monitor immune-related adverse events. Ongoing clinical studies that are investigating the potential role of ICIs in combination with other therapeutic approaches across varying cancer types will be highlighted.

GOALS

  • Physicians will be better able to recognize the potential benefits of CPIs in certain cancers through an improved understanding of their MOA & rationale for use. (Knowledge, Competence)
  • Physicians will be better able to apply the most up-to-date evidence on treatment subpopulations to inform CPI patient selection & improve the likelihood of success. (Knowledge, Competence)
  • Physicians will be more aware of the efficacy, safety & clinical implications, including selection & management, of approved & investigational CPI combinations. (Knowledge, Competence)
  • Physicians will be better prepared to implement appropriate strategies to manage the unique irAEs & response patterns that may occur in patients receiving CPIs. (Knowledge, Competence, Performance)

TARGET AUDIENCE

This is a targeted activity to Medical oncologists, surgeons and other healthcare providers. No prerequisites required.

EDUCATIONAL OBJECTIVES

At the conclusion of this educational activity, the participant should be able to:

  • Describe the MOA and molecular rationale for utilizing CPIs as a treatment for various solid tumors. (Knowledge, Competence)
  • Evaluate the most recent data on the efficacy of CPI in specific populations and lines of treatment to guide patient selection. (Knowledge, Competence)
  • Assess the clinical utility of current and emerging multimodal CPI combination treatment strategies. (Knowledge, Competence)
  • Propose strategies to recognize and manage irAEs and apparent disease progression in patients receiving CPIs. (Knowledge, Competence, Performance)

Release Date: April 22, 2019

Expiration Date: April 22, 2020

Estimated Time to Complete: 60 minutes

PARTICIPATING FACULTY

Adi Diab, MD (Course Director)
Assistant Professor
Department of Melanoma Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Mark M. Awad, MD, PhD
Assistant Professor, Medicine
Harvard Medical School
Medical Oncologist
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
Boston, Massachusetts

Arjun V. Balar, MD
Associate Professor of Medicine
Director of the Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

Nizar M. Tannir, MD, FACP
Professor and Deputy Chair
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

ACCREDITATION/CREDIT DESIGNATION

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this internet enduring material activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME CERTIFICATES AND ATTENDANCE CERTIFICATES

Certificates awarding AMA PRA Category 1 CreditTM or certificates documenting participation will be issued immediately to participants when an individual completes the post-test and evaluation.

Non-Physicians will receive a certificate of participation in accordance with state nursing boards, specialty societies, or other professional associations.

CME DISCLOSURE

The University of Texas MD Anderson Cancer Center Disclosure Policy for Program Chairs, Planning Committee Members, Teachers, or Authors and CME Activity Reviewers

The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer’s relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.

The University of Texas MD Anderson Cancer Center has, through a formal review process, made every attempt to resolve all potential conflicts of interest prior to this activity. For information on this process, please contact the CME/Conference Management at 713/792-5357.

The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

FACULTY/COMMERCIAL INTEREST
Mark M. Awad, MD, PhD: Grant or research support:
Bristol-Myers Squibb, Lilly, AstraZeneca, Genentech; Paid consultant: Bristol-Myers Squibb, Merck, AstraZeneca, Genentech, Pfizer, Syndax, Nektar, Blueprint

Arjun V. Balar, MD*: Grant or research support: Merck, Genentech; Paid consultant: Merck, Genentech, Roche, Pfizer, Incyte, AstraZeneca

Adi Diab, MD: Membership on advisory committees: Nektar Therapeutics, Idera Pharmaceuticals, Novartis Pharmaceuticals, Array Biopharma

Nizar M. Tannir, MD, FACP*: Honoraria: Pfizer, Nektar Therapeutics, Bristol-Myers Squibb, Novartis, Oncorena, Exelixis, Eisai Medical Research; Membership on advisory committee: Pfizer, Nektar Therapeutics, ARMO BioSciences, Oncorena

PLANNING COMMITTEE MEMBERS
Adi Diab, MD:
Membership on advisory committees:
Nektar Therapeutics, Idera Pharmaceuticals, Novartis Pharmaceuticals, Array Biopharma

CME ACTIVITY REVIEWERS/APPROVERS
Jeffrey H. Lee, MD:
Paid Consultant:
Boston Scientific

The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

PLANNING COMMITTEE MEMBERS: Tamara Greiner, MA, CHCP; Daniel Guinee; Jessica Marshal, PhD.
CME ACTIVITY REVIEWERS/APPROVERS: Diane C. Bodurka, MD, BS, MPH; A. Kyle Jones, PhD; Gary Whitman, MD

ACTIVITY INSTRUCTIONS

The following is an interactive enduring expert panel discussion designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, the enduring expert panel, and a CME postassessment and evaluation. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the activity.

TABLE OF CONTENTS

Preassessment

Evolving Considerations in Immuno-Oncology: Bridging the Gaps Between Research and Clinical Care

Faculty Panel

Postassessment and Evaluation